|
|
|
|
Prasco Signs Distribution, Supply Agreement With Axcan Pharma
Prasco to market the authorized generic versions of URSO Forte Scored and URSO 250 Prasco has entered into a distribution and supply agreement with Axcan for authorized generic versions of URSO 250 and URSO Forte Scored family of products.
|
|
|
Prasco and Axcan Pharma Sign a Distribution and Supply Agreement for Authorized Generic Versions of URSO F
Prasco Laboratories, a privately held pharmaceutical company located in Cincinnati, Ohio, announced today it has entered into a distribution and supply agreement with Axcan Pharma US, Inc.for Authorized Generic versions of URSO 250 and...
|
|
|
Cirrhosis: PPI use is associated with bacterial peritonitis
_ Cirrhosis: PPI use is associated with bacterial peritonitis.
Nature Clinical Practice Gastroenterology & Hepato:
Jul 3 2009 10:31AM
Matching: cirrhosis
|
Find similar documents
|
|
|
|
Prasco and Axcan Pharma Sign a Distribution and Supply Agreement for Authorized Generic Versions of
Prasco Laboratories, a privately held pharmaceutical company located in Cincinnati, Ohio, announced today it has entered into a distribution and supply agreement with Axcan Pharma US, Inc.for Authorized Generic versions of URSO 250 and...
|
|
|
Prasco and Axcan Pharma Sign a Distribution and Supply Agreement for Authorized Generic Versions of URSO Forte
- Prasco Will Market the Authorized Generic Versions of URSO ForteScored and URSO 250 (Ursodeoxycholic Acid, UDCA) - Prasco Expects to Launch Immediately CINCINNATI--(Business Wire)-- Prasco Laboratories, a privately held pharmaceutical...
|
|
|
Prasco and Axcan Pharma Sign a Distribution and Supply Agreement for Authorized Generic Versions of URSO Forte
CINCINNATI--(BUSINESS WIRE)--Prasco Laboratories, a privately held pharmaceutical company located in Cincinnati, Ohio, announced today it has entered into a distribution and supply agreement with Axcan Pharma US, Inc.for Authorized...
|
|
|
Prasco and Axcan Pharma(TM) Sign a Distribution and Supply Agreement for Authorized Generic
BusinessWire - --- Prasco Expects to Launch Immediately Prasco Laboratories, a privately held pharmaceutical company located in Cincinnati, Ohio, announced today it has entered into a distribution and supply agreement with Axcan Pharma US,...
|
|
|
Prasco and Axcan Pharma(TM) Sign a Distribution and Supply Agreement for Authorized Generic Versions of URSO F
o Expects to Launch Immediately Prasco Laboratories, a privately held pharmaceutical company located in Cincinnati, Ohio, announced today it has entered into a distribution and supply agreement with Axcan Pharma US, Inc.for Authorized...
|
|
|
Prasco and Axcan Pharma(TM) Sign a Distribution and Supply Agreement for Authorized Generic Versions of URSO F
CINCINNATI--(BUSINESS WIRE)-- Prasco Laboratories, a privately held pharmaceutical company located in Cincinnati, Ohio, announced today it has entered into a distribution and supply agreement with Axcan Pharma US, Inc.for Authorized...
|
|
|
Prasco and Axcan Pharma„ Sign a Distribution and Supply Agreement for Authorized Generic Versions of U
- Prasco Will Market the Authorized Generic Versions of URSO Forte Scored and URSO 250 (Ursodeoxycholic Acid, UDCA) - Prasco Expects to Launch Immediately CINCINNATI--(BUSINESS WIRE)--Prasco Laboratories, a privately held pharmaceutical...
|
|
|
Does Cirrhosis Affect Quality of Life in Hepatitis C Virus-infected Patients?
_ Does Cirrhosis Affect Quality of Life in Hepatitis C Virus-infected Patients?.
|
|
|
Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
_ Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants.
|
|
|
'Maintenance Therapy Did Not Reduce Incidence of HCC in the HALT-C Study'
'Data from several previous studies, mostly from Japan, suggested that long-term treatment with interferon-based regimens slowed progression of fibrosis and reduced the occurrence of HCC in persons with chronic hepatitis C virus (HCV)...
|
|
|
Clinical Features and Predictors of Outcome in Acute Hepatitis A and Hepatitis E Virus on Cirrhosis
_ Clinical Features and Predictors of Outcome in Acute Hepatitis A and Hepatitis E Virus on Cirrhosis.
|
|
|
Clinical Features and Predictors of Outcome in Acute Hepatitis A and Hepatitis E Virus on Cirrhosis
_ Clinical Features and Predictors of Outcome in Acute Hepatitis A and Hepatitis E Virus on Cirrhosis.
|
|
|
Simvastatin Lowers Portal Pressure in Patients With Cirrhosis, Portal Hypertension
_ Simvastatin Lowers Portal Pressure in Patients With Cirrhosis, Portal Hypertension.
|
|
|
Simvastatin Lowers Portal Pressure in Patients With Cirrhosis, Portal Hypertension
_ Simvastatin Lowers Portal Pressure in Patients With Cirrhosis, Portal Hypertension.
|
|
|
Are Angiotensins Involved In The Hemodynamic Changes Of Cirrhosis Patients?
Liver cirrhosis has been recently studied in the light of the new view of the renin angiotensin system (RAS).While the angiotensin converting enzyme (ACE)-Ang 2-AT1 receptor arm contributes to liver tissue injury and fibrosis...
|
|
|
Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
(Click the title below to leave the MDLinx Network and go to the Journal's Website) New England Journal of Medicine, 06/11/09 Print Save in My Library Free Abstract Hirschfield GM et al.- The data show significant associations between...
|
|
|
Cirrhosis - Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. Mayo Researchers Help Discover Genetic Cause...
|
|
|
Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
_ Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants.
|
|
|
Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
- Company preparing to initiate phase II trial in hepatic encephalopathy - SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire/ -- Hyperion Therapeutics, Inc.today announced top-line results from a phase I study of HPN-100 in patients with ...
|
|
|
Hyperion Therapeutics Announces Results Of Phase I Study In Patients With Liver Cirrhosis
Hyperion Therapeutics, Inc.announced top-line results from a phase I study of HPN-100 in patients with liver cirrhosis. The data were presented as part of the 2009 Digestive Disease Week meeting. The abstract is titled ...
|
|
|
Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
- Company preparing to initiate phase II trial in hepatic encephalopathy - SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire/ -- Hyperion Therapeutics, Inc.today announced top-line results from a phase I study of HPN-100 in patients with ...
|
|
|
Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
- Company preparing to initiate phase II trial in hepatic encephalopathy - SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire/ -- Hyperion Therapeutics, Inc.today announced top-line results from a phase I study of HPN-100 in patients with ...
|
